POLPHARMA-BIOLOGICS
4.10.2021 11:33:12 CEST | Business Wire | Press release
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application (BLA) for its proposed biosimilar (formally also known as BQ201, FYB201, CHS-201) to Lucentis® , a blockbuster ophthalmological drug containing ranibizumab as active drug substance, has been accepted for review.
The FDA has assigned a target action date for the application for August 2022.
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product.
This file acceptance represents the most recent milestone for Bioeq`s ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA in June and UK MHRA in July this year.
Subject to the FDA`s approval, BQ201 will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented on the achievements of the joint venture:
“This file acceptance is validation of the huge effort put in by the team at Bioeq and its partners to bring treatment choice and improved patient access to the US market. It creates real promise for those who suffer from debilitating vision loss, including age-related macular degeneration.”
- Lucentis® is a registered trademark of Genentech Inc.
Information for editors
About Ranibizumab biosimilar
Bioeq`s proposed ranibizumab biosimilar BQ201, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis® .
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005408/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Energie Selects Kraken to Manage Wind, Solar and Storage6.5.2026 09:00:00 CEST | Press release
Kraken operating system to manage Pure Energie’s growing portfolio on one intelligent platformPure Energie to benefit from seamless co-ordination across customer load, wind, solar and batteries – maximizing asset value while helping to balance the grid20 sites to onboard in H1 2026, with further expansion planned Pure Energie, a Dutch clean energy company, has selected Kraken – the AI-powered operating system transforming global utilities – to manage and optimize its consumer, wind, solar and battery portfolio across the Netherlands. Kraken brings together grid-scale assets and consumer demand on the same platform, co-ordinating them as a single, intelligent portfolio. This enables Pure Energie to optimize demand and generation in real time – maximizing asset value and helping reduce imbalance costs. The partnership will deliver an energy management system which includes retail balancing, day-ahead curtailment, intraday trading, imbalance optimization, and ancillary market access, alon
Thredd and Currensea Expand Strategic Partnership to Power Next Phase of Growth6.5.2026 09:00:00 CEST | Press release
Four-year renewal builds on long-standing collaboration supporting the payments technology platform behind co-branded reward-earning debit cards and the UK’s top-rated travel spending card Thredd, the AI-first issuer processing platform, today announced the renewal and extension of its longstanding partnership with Currensea, the market-leading payments technology platform. The new agreement extends the relationship for an additional four years, reinforcing a collaboration that has been in place since 2019. Currensea has built a strong reputation among travellers with its multi-bank travel card that links directly to customers’ existing bank accounts, offering competitive FX rates without the need to preload funds. In recent years, Currensea has expanded its offering through co-brand partnerships with leading global travel and hospitality brands, including Hilton Hotels, Marriott Bonvoy and United Airlines, allowing cardholders to earn competitive rewards on their day-to-day debit spen
AMINA Becomes First Bank to Support Canton Coin Trading and Custody6.5.2026 08:30:00 CEST | Press release
Swiss-regulated AMINA provides clients with regulated access to the network that DTCC, Visa, BitGo, and others are building on AMINA Bank AG ("AMINA"), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first bank to support Canton Coin (CC), the native token of Canton Network, offering custody and trading services to its clients. Canton Network is a public, privacy-preserving blockchain built for capital markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505860056/en/ AMINA Becomes First Bank to Support Canton Coin Trading and Custody Canton has gained significant institutional momentum in recent months, attracting TradFi and DeFi organizations, including the DTCC, Visa, and BitGo, that are building next-generation settlement, tokenisation, custody, and collateral workflows on the network. Canton is also developing an on-chain capital markets ecosystem t
Novatus Global Receives a King’s Award for Enterprise6.5.2026 08:00:00 CEST | Press release
Novatus Global Limited (“Novatus” “Novatus Global” or “the Company”), an award-winning provider of regulatory technology solutions and consulting services to global financial institutions, has been honoured with a King’s Award for Enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505378016/en/ Novatus is one of only 185 organisations nationally to be recognised with a prestigious King’s Award for Enterprise in 2026. Announced today (Wednesday 6 May), the Award acknowledges the company’s outstanding achievement in Innovation. Novatus Global, founded in 2019, employs over 100 people across London, the U.S., Australia, and India and has rapidly established itself as a trusted partner to many of the world’s leading banks, asset managers, and financial institutions. Its flagship product, Novatus En:ACT, is a market-leading SaaS platform delivering complete, real-time assurance across global transaction reporting regim
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom